Drug Profile


Alternative Names: Latuda; Lurasidone HCl; Lurasidone hydrochloride; SM-13496; SMP-13496

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer DKSH Singapore; DKSH Thailand; Standard Chemical & Pharmaceutical Company; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals; Takeda
  • Class Antipsychotics; Cyclohexanes; Isoindoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Preregistration Bipolar disorders
  • Phase III Autistic disorder; Major depressive disorder
  • Phase I Psychiatric disorders

Most Recent Events

  • 31 Oct 2016 Preregistration for Schizophrenia (In adolescents) in USA (PO)
  • 27 Oct 2016 Efficacy, adverse events and pharmacodynamics data from a phase III trial in Schizophrenia (In adolescents) released by Sunovion
  • 01 Oct 2016 Sunovion completes a phase III trial in Bipolar depression (In adolescents, In children, Monotherapy) in USA, Bulgaria, Colombia, France, Hungary, Mexico, Philippines, Poland, Puerto Rico, South Korea, Ukraine and United Kingdom (NCT02046369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top